OverweightMETAVO-ONENCT07354308
Study to Evaluate the Efficacy of an Avocado Dietary Supplement
A study testing Metavo Supplement in people with Overweight and Metabolic Health, run by SP Nutraceuticals Inc. at 1 site in United States.
Trial summary
This 16-week, randomized, triple-blinded, placebo-controlled study evaluates the effects of an avocado dietary supplement (Metavo) on healthy weight and blood glucose management in overweight adults. Read more about this study
- Who is it for?
- Ages 18 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Overweight, Metabolic Health, Insulin Resistance
- What is being tested?
- Metavo Supplement
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteUnited States
- Study dates
- 1 May 2025to Jan 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Be male or female
- Be aged between 18 and 70 years of age
- Be classified as overweight or obese with a BMI of ≥25.0 and ≤32 kg/m2.
- Have a stable weight defined as <10% change in body weight in three months prior to the study start date.
- Willing to follow the provided diet and exercise guidelines.
- Willing to not consume avocados throughout the trial and for two weeks prior to Baseline
Show all 13Show fewer
- Anyone who is generally healthy - does not live with any uncontrolled chronic disease.
- Willing to stop any products, any prescription medication, or supplements that target weight management, blood sugar control, and/or aim to improve insulin during the test period.
- Willing to avoid introducing any new products or any new forms of prescription medication or supplements that target weight management, blood sugar control, and/or aim to improve insulin during the test period.
- Not currently partaking in another research study and will not be partaking in any other research study for the next 16 weeks and at any point during this study's duration.
- Must have someone available to take front and side profiles of the torso.
- Must have a smart phone or camera capable of taking photos of the torso.
- Resides in the United States.
Who cannot join
- Anyone with diagnosed Type I or Type II diabetes.
- Allergic to avocados
- Anyone with any allergies or sensitivities to any of the study product ingredients.
- Any women who are pregnant, breastfeeding, or trying to conceive
- Anyone unwilling to follow the study protocol.
- Has stopped using hormonal birth control in the past month.
Show all 13Show fewer
- Anyone with a history of substance abuse.
- Anyone who is currently a smoker or has been a smoker in the past 6 months.
- Anyone with chronic health conditions that could impact participation in the study, such as oncological, psychiatric, metabolic, hypertension, or cardiovascular disorders, cancer, autoimmune disease, HIV, Hepatitis B, and/or C, kidney and/or liver, gastrointestinal, gastroesophageal reflux, blood/bleeding disorders, gout, or mental health disorders.
- Anyone who has had any major illness in the last 3 months.
- Anyone who drinks heavily (i.e., 8 or more alcoholic drinks per week for women or 15 or more alcoholic drinks per week for men).
- Current use of prescribed medications as listed below: Weight loss prescription medication (within 3 months of baseline). Anticoagulants and coagulants (within 4 weeks of baseline).
- Anyone who has used any cannabis products (medical or recreational) in the past month.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Study to Evaluate the Efficacy of an Avocado Dietary Supplement to Support Healthy Weight and Blood Glucose Management
This 16-week, randomized, triple-blinded, placebo-controlled study evaluates the effects of an avocado dietary supplement (Metavo) on healthy weight and blood glucose management in overweight adults. The study includes body measurements, questionnaires, blood tests, and CGM monitoring to assess metabolic outcomes and participant-reported perceptions of well-being.
- Conditions
- Overweight, Metabolic Health, Insulin Resistance
- Being tested
- Metavo Supplement, Placebo
- Keywords
- Weight Management, Glucose Metabolism, avocado
- Medical subject headings
- Overweight, Insulin Resistance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Metavo SupplementDietary supplement
Participants will take 8 Intervention capsules per day (4 in the morning, 4 in the afternoon)
PlaceboDietary supplement
Participants will take 8 placebo capsules per day (4 in the morning, 4 in the afternoon)
| Study group | Role | What they receive |
|---|---|---|
| Metavo Supplement Group | Experimental | Participants in this group will receive the Metavo dietary supplement for 16 weeks. Receives: Dietary Supplement: Metavo Supplement |
| Placebo Group | Placebo comparator | Participants in this group will receive placebo capsules that are visually matched to the Metavo supplement for 16 weeks. Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Body Mass
Measured via Withings Smart Scale. Participants will weigh themselves daily for 3 consecutive days each week. If the first two values are similar, their average is used. If they differ by ≥10 lbs, the third value is used to determine the average.
Measured: Baseline through Week 16
Change in Average Blood Glucose
Change in average blood glucose levels measured using a Continuous Glucose Monitor (CGM). Average glucose will be calculated over each time period and the change from pre-baseline to Weeks 14-16 will be reported.
Measured: 2 weeks before Baseline and Weeks 14-16
Change in Hemoglobin A1C (HbA1C)
Assessed via blood samples at Labcorp or via home phlebotomy.
Measured: Baseline and Week 16
Change in Fasting Insulin
Assessed via blood samples at Labcorp or via home phlebotomy.
Measured: Baseline and Week 16
Change in Lipid Panel
Includes Cholesterol, LDL, VLDL, HDL, and triglycerides. Measured via Labcorp or home phlebotomy.
Measured: Baseline and Week 16
Change in hs-CRP
High-sensitivity C-reactive protein measured via Labcorp or home phlebotomy.
Measured: Baseline and Week 16
Change in Fasting GLP-1 Levels
Only measured in the home phlebotomy subgroup using InterScience Institute lab testing.
Measured: Baseline and Week 16
Change in Waist Circumference
Measured with a tape measure.
Measured: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Change in Time in Range (TIR)
Change in percentage of time that glucose levels are within the target range, measured using a CGM. TIR will be computed as the percentage of total CGM readings within the target range during the specified time periods.
Measured: 2 weeks before Baseline and Weeks 14-16
Change in Time Below Range (TBR)
Change in percentage of time that glucose levels are below the target range, measured using a CGM. TBR will be calculated as the percentage of total CGM readings below the target range.
Measured: 2 weeks before Baseline and Weeks 14-16
Change in Time Above Range (TAR)
Change in percentage of time that glucose levels are above the target range, measured using a CGM. TAR will be calculated as the percentage of total CGM readings above the target range.
Measured: 2 weeks before Baseline and Weeks 14-16
Secondary outcomes (11)
Change in Quality of Life
Evaluated using the Short Form-12 (SF-12) questionnaire.
Measured: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Change in Physical Activity
Evaluated using the Godin Leisure-Time Exercise Questionnaire (GLTE).
Measured: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Change in Eating Habits
Evaluated using the Three-Factor Eating Questionnaire - Revised 21 (TFEQ-R21).
Measured: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Change in Food Cravings
Evaluated using the Food Craving Questionnaire - Trait reduced (FCQ-T reduced).
Measured: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Change in Self-Reported Mood, Energy, and Health
Participants report changes in energy levels, weight perception, mood, and general well-being.
Measured: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Change in Total Muscle Mass (kg)
Total skeletal muscle mass measured in kilograms using a Withings smart scale via Bioelectrical Impedance Analysis (BIA).
Measured: Weekly from Baseline to Week 16
Change in Total Body Fat Mass (kg)
Total weight of body fat measured in kilograms using a Withings smart scale via Bioelectrical Impedance Analysis (BIA).
Measured: Weekly from Baseline to Week 16
Change in Bone Mass (kg)
Estimated weight of bone mineral content in kilograms, measured using a Withings smart scale via Bioelectrical Impedance Analysis (BIA).
Measured: Weekly from Baseline to Week 16
Change in Total Lean Mass (kg)
Total fat-free mass (including muscle, bone, and water) measured in kilograms using a Withings smart scale via Bioelectrical Impedance Analysis (BIA).
Measured: Weekly from Baseline to Week 16
Change in Total Body Water Percentage (%)
Total body water as a percentage of total body weight, measured using a Withings smart scale via Bioelectrical Impedance Analysis (BIA).
Measured: Weekly from Baseline to Week 16
Change in Visceral Fat Index
An indexed score representing the amount of visceral fat (the fat surrounding internal organs) measured via a Withings smart scale. This index typically ranges from 1 to 20, where higher scores indicate higher visceral fat levels.
Measured: Weekly from Baseline to Week 16
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Jan 2026
- Study start1 May 2025
- Primary completionJan 2026 (estimated)
- Study completionJan 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for OverweightStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- SP Nutraceuticals Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07354308
- Sponsor's protocol ID
- 20710
- Acronym
- METAVO-ONE
- Status last verified
- Jan 2026
- First submitted
- 6 Dec 2025
- Last updated
- 21 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Study to Evaluate the Efficacy of an Avocado Dietary Supplement to Support Healthy Weight and Blood Glucose Management
- ClinicalTrials.gov ID
- NCT07354308
- Acronym / sponsor ID
- METAVO-ONE / 20710
- Conditions
- Overweight, Metabolic Health, Insulin Resistance
- Keywords
- Weight Management, Glucose Metabolism, avocado
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- SP Nutraceuticals Inc.Industry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Study start
- 1 May 2025 (actual)
- Primary completion
- Jan 2026 (estimated)
- Study completion
- Jan 2026 (estimated)
- First posted
- 21 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This 16-week, randomized, triple-blinded, placebo-controlled study evaluates the effects of an avocado dietary supplement (Metavo) on healthy weight and blood glucose management in overweight adults. The study includes body measurements, questionnaires, blood tests, and CGM monitoring to assess metabolic outcomes and participant-reported perceptions of well-being.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Metavo Supplement Group | Experimental | Dietary Supplement: Metavo SupplementParticipants in this group will receive the Metavo dietary supplement for 16 weeks. |
| Placebo Group | Placebo comparator | Dietary Supplement: PlaceboParticipants in this group will receive placebo capsules that are visually matched to the Metavo supplement for 16 weeks. |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (13 listed)
- Be male or female
- Be aged between 18 and 70 years of age
- Be classified as overweight or obese with a BMI of ≥25.0 and ≤32 kg/m2.
- Have a stable weight defined as <10% change in body weight in three months prior to the study start date.
- Willing to follow the provided diet and exercise guidelines.
Key exclusion criteria (13 listed)
- Anyone with diagnosed Type I or Type II diabetes.
- Allergic to avocados
- Anyone with any allergies or sensitivities to any of the study product ingredients.
- Any women who are pregnant, breastfeeding, or trying to conceive
- Anyone unwilling to follow the study protocol.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Metavo SupplementParticipants will take 8 Intervention capsules per day (4 in the morning, 4 in the afternoon) | Dietary supplement | Metavo Supplement Group |
| PlaceboParticipants will take 8 placebo capsules per day (4 in the morning, 4 in the afternoon) | Dietary supplement | Placebo Group |
Primary outcome
Change in Body Mass
Time frame: Baseline through Week 16
Measured via Withings Smart Scale. Participants will weigh themselves daily for 3 consecutive days each week. If the first two values are similar, their average is used. If they differ by ≥10 lbs, the third value is used to determine the average.
Change in Average Blood Glucose
Time frame: 2 weeks before Baseline and Weeks 14-16
Change in average blood glucose levels measured using a Continuous Glucose Monitor (CGM). Average glucose will be calculated over each time period and the change from pre-baseline to Weeks 14-16 will be reported.
Change in Hemoglobin A1C (HbA1C)
Time frame: Baseline and Week 16
Assessed via blood samples at Labcorp or via home phlebotomy.
Change in Fasting Insulin
Time frame: Baseline and Week 16
Assessed via blood samples at Labcorp or via home phlebotomy.
Change in Lipid Panel
Time frame: Baseline and Week 16
Includes Cholesterol, LDL, VLDL, HDL, and triglycerides. Measured via Labcorp or home phlebotomy.
Change in hs-CRP
Time frame: Baseline and Week 16
High-sensitivity C-reactive protein measured via Labcorp or home phlebotomy.
Change in Fasting GLP-1 Levels
Time frame: Baseline and Week 16
Only measured in the home phlebotomy subgroup using InterScience Institute lab testing.
Change in Waist Circumference
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Measured with a tape measure.
Change in Time in Range (TIR)
Time frame: 2 weeks before Baseline and Weeks 14-16
Change in percentage of time that glucose levels are within the target range, measured using a CGM. TIR will be computed as the percentage of total CGM readings within the target range during the specified time periods.
Change in Time Below Range (TBR)
Time frame: 2 weeks before Baseline and Weeks 14-16
Change in percentage of time that glucose levels are below the target range, measured using a CGM. TBR will be calculated as the percentage of total CGM readings below the target range.
Change in Time Above Range (TAR)
Time frame: 2 weeks before Baseline and Weeks 14-16
Change in percentage of time that glucose levels are above the target range, measured using a CGM. TAR will be calculated as the percentage of total CGM readings above the target range.
11 secondary outcomes
Change in Quality of Life
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Change in Physical Activity
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Change in Eating Habits
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Change in Food Cravings
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Change in Self-Reported Mood, Energy, and Health
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Change in Total Muscle Mass (kg)
Time frame: Weekly from Baseline to Week 16
Change in Total Body Fat Mass (kg)
Time frame: Weekly from Baseline to Week 16
Change in Bone Mass (kg)
Time frame: Weekly from Baseline to Week 16
Change in Total Lean Mass (kg)
Time frame: Weekly from Baseline to Week 16
Change in Total Body Water Percentage (%)
Time frame: Weekly from Baseline to Week 16
Change in Visceral Fat Index
Time frame: Weekly from Baseline to Week 16
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Jan 2026.
Related trials for Overweight
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Metavo Supplement in people with Overweight and Metabolic Health, run by SP Nutraceuticals Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 21 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Body Mass (time frame: Baseline through Week 16). The study lists 11 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jan 2026.